11/16
03:06 am
fold
Amicus Therapeutics, Inc. (NASDAQ: FOLD) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Low
Report
Amicus Therapeutics, Inc. (NASDAQ: FOLD) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
11/12
10:45 am
fold
Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its price target raised by analysts at JPMorgan Chase & Co. from $16.00 to $17.00. They now have an "overweight" rating on the stock.
Low
Report
Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its price target raised by analysts at JPMorgan Chase & Co. from $16.00 to $17.00. They now have an "overweight" rating on the stock.
11/8
07:08 am
fold
Amicus Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
Low
Report
Amicus Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
11/7
02:34 pm
fold
Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its price target raised by analysts at Guggenheim from $13.00 to $15.00. They now have a "buy" rating on the stock.
Low
Report
Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its price target raised by analysts at Guggenheim from $13.00 to $15.00. They now have a "buy" rating on the stock.
11/7
12:35 pm
fold
Amicus' Q3 Earnings & Revenues Beat Estimates, '24 View Updated [Yahoo! Finance]
Low
Report
Amicus' Q3 Earnings & Revenues Beat Estimates, '24 View Updated [Yahoo! Finance]
11/7
11:31 am
fold
Here's Why Amicus Therapeutics (FOLD) is a Strong Momentum Stock [Yahoo! Finance]
Low
Report
Here's Why Amicus Therapeutics (FOLD) is a Strong Momentum Stock [Yahoo! Finance]
11/7
11:20 am
fold
Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its price target raised by analysts at Cantor Fitzgerald from $20.00 to $21.00. They now have an "overweight" rating on the stock.
Low
Report
Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its price target raised by analysts at Cantor Fitzgerald from $20.00 to $21.00. They now have an "overweight" rating on the stock.
11/7
08:36 am
fold
Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
Low
Report
Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
11/7
02:19 am
fold
Amicus Therapeutics Inc (FOLD) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
Low
Report
Amicus Therapeutics Inc (FOLD) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
11/6
10:25 pm
fold
Here's What Key Metrics Tell Us About Amicus Therapeutics (FOLD) Q3 Earnings [Yahoo! Finance]
Low
Report
Here's What Key Metrics Tell Us About Amicus Therapeutics (FOLD) Q3 Earnings [Yahoo! Finance]
11/6
10:15 am
fold
Amicus Therapeutics (FOLD) Q3 Earnings and Revenues Beat Estimates [Yahoo! Finance]
Low
Report
Amicus Therapeutics (FOLD) Q3 Earnings and Revenues Beat Estimates [Yahoo! Finance]
11/6
07:00 am
fold
Amicus Therapeutics Announces Third Quarter 2024 Financial Results and Corporate Updates
Medium
Report
Amicus Therapeutics Announces Third Quarter 2024 Financial Results and Corporate Updates
11/5
11:23 am
fold
Amicus Therapeutics Q3 2024 Earnings Preview Nov. 05, 2024 11:20 AM ET By: Jaskiran Singh , SA News Editor [Seeking Alpha]
Low
Report
Amicus Therapeutics Q3 2024 Earnings Preview Nov. 05, 2024 11:20 AM ET By: Jaskiran Singh , SA News Editor [Seeking Alpha]
11/4
11:43 am
fold
Wall Street Analysts Predict a 51.09% Upside in Amicus Therapeutics (FOLD): Here's What You Should Know [Yahoo! Finance]
Low
Report
Wall Street Analysts Predict a 51.09% Upside in Amicus Therapeutics (FOLD): Here's What You Should Know [Yahoo! Finance]
11/1
07:00 am
fold
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024
Low
Report
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024
10/31
02:04 am
fold
Amicus Therapeutics, Inc. (NASDAQ: FOLD) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Low
Report
Amicus Therapeutics, Inc. (NASDAQ: FOLD) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
10/28
07:00 am
fold
Amicus Therapeutics to Announce Third Quarter 2024 Financial Results on November 6, 2024
Medium
Report
Amicus Therapeutics to Announce Third Quarter 2024 Financial Results on November 6, 2024
10/23
02:07 am
fold
Amicus Therapeutics, Inc. (NASDAQ: FOLD) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Medium
Report
Amicus Therapeutics, Inc. (NASDAQ: FOLD) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
10/21
11:44 am
fold
Why Amicus Therapeutics (FOLD) is a Top Momentum Stock for the Long-Term [Yahoo! Finance]
Low
Report
Why Amicus Therapeutics (FOLD) is a Top Momentum Stock for the Long-Term [Yahoo! Finance]
10/18
03:52 pm
fold
Amicus: Teva Settlement Clears Revenue Path Forward For Galafold [Seeking Alpha]
Low
Report
Amicus: Teva Settlement Clears Revenue Path Forward For Galafold [Seeking Alpha]
10/18
01:48 pm
fold
Can Amicus Therapeutics (FOLD) Run Higher on Rising Earnings Estimates? [Yahoo! Finance]
Low
Report
Can Amicus Therapeutics (FOLD) Run Higher on Rising Earnings Estimates? [Yahoo! Finance]
10/18
11:47 am
fold
Amicus Therapeutics (FOLD) Just Flashed Golden Cross Signal: Do You Buy? [Yahoo! Finance]
Low
Report
Amicus Therapeutics (FOLD) Just Flashed Golden Cross Signal: Do You Buy? [Yahoo! Finance]
10/18
11:47 am
fold
How Much Upside is Left in Amicus Therapeutics (FOLD)? Wall Street Analysts Think 43.44% [Yahoo! Finance]
Low
Report
How Much Upside is Left in Amicus Therapeutics (FOLD)? Wall Street Analysts Think 43.44% [Yahoo! Finance]
10/17
01:37 pm
fold
Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its price target raised by analysts at Bank of America Co. from $13.00 to $15.00. They now have a "buy" rating on the stock.
Low
Report
Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its price target raised by analysts at Bank of America Co. from $13.00 to $15.00. They now have a "buy" rating on the stock.
10/17
07:00 am
fold
Amicus Therapeutics Announces Settlement of Galafold® (migalastat) Patent Litigation with Teva
High
Report
Amicus Therapeutics Announces Settlement of Galafold® (migalastat) Patent Litigation with Teva